Teva sees return to growth after opioid settlement, shares jump
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Pharma (TEVA) Shares Surge on Proposed Opioid Settlement, Earnings Beat
July 27, 2022 11:44 AM EDTShares of Teva Pharma (NYSE: TEVA) jumped over 24% in early Wednesday trading following the announcement of its second-quarter results and an agreement, in principle, on a nationwide opioid settlement.
The company beat earnings and revenue forecasts, posting a profit of $0.68 per share on revenue of $3.79 billion. Analysts expected earnings per share of $0.56 on revenue of $3.78 billion.
However, it is the company's opioid settlement announcement that has caught the attention of... More
